Compare ARRY & SANA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | ARRY | SANA |
|---|---|---|
| Founded | 1989 | 2018 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Semiconductors | Medicinal Chemicals and Botanical Products |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.2B | 1.4B |
| IPO Year | 2020 | 2021 |
| Metric | ARRY | SANA |
|---|---|---|
| Price | $9.23 | $3.24 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 19 | 5 |
| Target Price | ★ $10.21 | $7.80 |
| AVG Volume (30 Days) | ★ 4.9M | 4.1M |
| Earning Date | 05-06-2026 | 05-07-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 62.56 | 17.24 |
| EPS | ★ N/A | N/A |
| Revenue | ★ $1,284,141,000.00 | N/A |
| Revenue This Year | $15.72 | N/A |
| Revenue Next Year | $8.08 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 40.22 | N/A |
| 52 Week Low | $5.39 | $2.26 |
| 52 Week High | $12.23 | $6.55 |
| Indicator | ARRY | SANA |
|---|---|---|
| Relative Strength Index (RSI) | 60.66 | 49.57 |
| Support Level | $7.69 | $2.89 |
| Resistance Level | $9.65 | $3.43 |
| Average True Range (ATR) | 0.58 | 0.19 |
| MACD | 0.05 | 0.01 |
| Stochastic Oscillator | 83.97 | 67.74 |
Array Technologies Inc manufacturer of ground-mounting systems used in solar energy projects. The company's segments include: the Array legacy operating segment (Array Legacy Operations) and the STI Operations operating segment (STI Operations). It derives maximum revenue from the Array legacy operating segment. Its product is an integrated system of steel supports, electric motors, gearboxes, and electronic controllers referred to as a single-axis tracker that moves solar panels throughout the day to maintain an optimal orientation to the sun, which increases their energy production. Geographically, the company's operations are in the United States, Australia, Spain, Brazil, and the rest of the world, with the United States deriving the majority of the revenue.
Sana Biotechnology Inc is a biotechnology company. The company develops engineered cells as medicines and therapies to treat diseases. It is engaged in developing cell engineering programs for across a broad array of therapeutic areas with unmet treatment needs, including oncology, diabetes, B-cell-mediated autoimmune, and central nervous system (CNS) disorders, among others. Its pipeline of product candidates is comprised of SC291, SC262, SC255, UP421 and others.